This aligns with the findings of myocarditis research demonstrating that PX‐478 could alleviate the inflammatory responses by means of HIF1A inhibition.[37] In addition, our study revealed that the administration of PX‐478, a commercially available inhibitor of HIF1A,[38] exhibited therapeutic efficacy in a murine OA model, as evidenced by a decrease in the population of synovial iNOS‐expressing macrophages and ameliorated cartilage degeneration. Here, HIF1A is linked to myocarditis.